These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 15735795

  • 1. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
    Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ, International Kogenate-FS Study Group.
    Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.
    Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R.
    Haemophilia; 2007 Jul; 13(4):351-6. PubMed ID: 17610547
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs).
    Giangrande PL, KOGENATE Bayer Study Group.
    Haemophilia; 2002 Mar; 8 Suppl 2():19-22. PubMed ID: 11966848
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients.
    Rothschild C, Scharrer I, Brackmann HH, Stieltjes N, Vicariot M, Torchet MF, Effenberger W.
    Haemophilia; 2002 Mar; 8 Suppl 2():10-4. PubMed ID: 11966846
    [Abstract] [Full Text] [Related]

  • 9. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K, Rauchensteiner S, Santagostino E, Platokouki H, Schutgens RE, Brunn M, Tueckmantel C, Valeri F, Schinco PC.
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [Abstract] [Full Text] [Related]

  • 10. Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study.
    Klamroth R, Miesbach W, Staritz P, German EffeKt Study Group.
    Haemophilia; 2016 Sep; 22(5):684-91. PubMed ID: 27030540
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
    Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D.
    Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
    Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, Kogenate Post-Marketing Surveillance Study Group.
    Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
    Spira J, Plyushch OP, Andreeva TA, Khametova RN.
    Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A, Windyga J, Batorova A.
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.